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Summary: The relative proportions of the four coproporphyrin isomers I—IV were analysed in faeces of 20 healthy
subjects and 60 patients suffering from one of the seven common types of hepatic or erythropoietic hereditary
porphyrias. A newly developed, reliable method for sample preparation was applied, using reversed-phase thin-
layer chromatography for the isolation of naturally occurring coproporphyrin free carboxylic acids. Accurate separa-
tion and quantitation of the individual isomers I—IV were achieved with the help of ion-pair high-performance
liquid chromatography. The four coproporphyrin isomers I—IV were positively identified by on-line scanning of
their fluorescence spectra in the emission and excitation modes. Recovery rates with this new analytical procedure
were between 90 and 100%, and coefficients of variation varied between 0.8 and 5.7% (N = 7).
Diagnostically important findings were greatly increased proportions of isomer I and decreased proportions of
isomers III, II and IV in erythropoietic porphyrias, such as congenital erythropoietic porphyria and protoporphyria.
Significantly increased proportions of isomers III, II and IV, on the other hand, were observed in acute hepatic
porphyrias, e. g. acute intermittent porphyria and porphobilinogen synthase deficiency porphyria, as compared with
porphyria cutanea tarda (p < 0.005 and p < 0.03, respectively).
Inversion of the faecal coproporphyrin to I ratios and markedly elevated percentages of the atypical isomers II
and IV were important diagnostic markers for variegate porphyria and hereditary coproporphyria. The highest
proportions of isomer III were found in hereditary coproporphyria, where the amount of the isomers II and IV
exceeded that of isomer I. Asymptomatic carriers of the relevant gene defect in families with hereditary copropor-
phyria could be detected by an increased faecal coproporphyrin III to I ratio.
Our results clearly demonstrate the potential of faecal coproporphyrin I—IV isomer ratios for the diagnosis and
differential diagnosis of hereditary porphyrias.
Introduction
The porphyrias arise from inherited or acquired disor- Routes of elimination of different porphyrins mainly
ders of enzymes in the haem biosynthetic pathway, re- depend on the polarity of their molecular structure,
suiting in excessive production of porphyrins or porphy- The highly polar uroporphyrin, carrying eight carboxyl
rin precursors (1). groups, is predominantly found in urine, whereas the
apolar protoporphyrin is excreted exclusively via bile
~ ,_
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 and
 faeces. The medium polarity of coproporphyrinJ) Presented m part at the "International Symposium on Porphynas . .
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and Heme Related Disorders", June 28-July 2, »95, Helsinki, results m excretion by both renal and hepatobihary
Finland. routes.
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The diagnosis of porphyrias is-based on the analysis of
porphyrins and porphyrin precursors in clinical materi-
als, e.g., urine, faeces and blood (1, 2). Measurement of
faecal porphyrins is particularly helpful for diagnosing
the different acute hepatic porphyrias: acute intermittent
porphyria, variegate porphyria, hereditary copropor-
phyria and porphobilinogen synthase deficiency por-
phyria. Increased faecal porphyrin excretion is also ob-
served in chronic porphyrias, such as congenital erythro-
poietic porphyria, porphyria cutanea tarda and proto-
porphyria. The determination of porphyrin isomer ratios
provides additional information for the differential diag-
nosis of porphyrias, especially when the ratio of copro-
porphyrin isomers I and III is altered (3, 4). Finally, the
analysis of haem biosynthetic enzyme activities allows
the identification of the causative enzyme deficiency in
patients and often also in asymptomatic family members
carrying the defective gene (1).
In a recent study, we analysed the relative proportions
of the four ppproporphyrin isomers I—IV in urine of
patients suffering from the common types of hereditary
porphyria (4). We observed significantly increased pro-
portions of coproporphyrin III in acute hepatic porphyr-
ias as compared with chronic hepatic porphyrias. In con-
trast, the highest proportion of coproporphyrin I was
found in congenital erythropoietic porphyria which re-
sults from a defect of uroporphyrinogen III cosyn-
thase2). The atypical coproporphyrin isomers II and IV
were present in all types of porphyria investigated, but
did not provide additional diagnostic information. Here,
we report results of a subsequent study of the excretion
of the four coproporphyrin isomers I-IV in faeces from
patients with the common types of hereditary porphyr-
ias. Application of a newly developed reversed-phase
thin-layer Chromatographie (TLC) method allowed a
highly selective isolation of free faecal coproporphyrins
I—IV, which were completely separated and quantitated
by isocratic ion-pair high-performance liquid chroma-
tography (HPLC) (5). Another aim of this study was to
compare the results of faecal and urinary coproporphy-
rin isomer ratios in the corresponding types of porphyria,
and to evaluate the diagnostic relevance of faecal copro-
porphyrin isomers I-IV.
Materials and Methods
Patients
Stool samples were analysed from 20 healthy subjects (12 males,
8 females, 21 to 49 years old) and 60 patients suffering from the
2) Enzymes
Coproporphyrinogen oxidase (EC 1.3.3.3)
Porphobilinogen synthase (EC 4.2.1.24) ·
Protoporphyrinogen oxidase (EC 1.3.3.4)
Uroporphyrinogen III cosynthase (EC 4.2.1.75)
following types of porphyria: congenital erythropoietic porphyria
(N = 6), erythrohepatic protoporphyria (N = 7), porphyria cuta-
nea tarda (N = 13), acute intermittent porphyria (N = 15),
porphobilinogen synthase deficiency porphyria (N = 2), varie-
gate porphyria (N = 7), hereditary coproporphyria (N = 10). Di-
agnosis of the respective porphyrias was based on biochemical
measurements and characteristic clinical symptoms in manifest
cases. . r
Table 1 shows the clinical status and faecal porphyrin excretion
of seven selected patients with different types of hereditary por-
phyria.
Stool samples
Stool samples were protected from light, freeze-dried and kept fro-
zen at -20 °C until analysis.
Analysis of faecal protoporphyrin and total
coproporphyrins
Total coproporphyrins and protoporphyrin in faeces were deter-
mined by the high-performance thin-layer Chromatographie method
of Doss (1).
Sample preparation for determination of
coproporphyrins I —IV
Faeces (10 to 100 mg, depending on the respective content of total
coproporphyrins) were suspended in 2 ml 9 g/1 aqueous NaCl, oxi-
Tab. 1 Faecal porphyrins in seven patients with different types
of porphyria.
Porphyria Total Proto-
coproporphyrins porphyrin
(nmol/g (nmol/g
dry weight) dry weight)
Congenital erythropoietic 146
porphyria, male, 24 years
old, cutaneous phase (fig. la)
Protoporphyria, male, 56 26
years old, after liver trans-
plantation, mild photoderma-
tosis
Porphyria cutanea tarda, 17
male, 53 years old,
non-acute phase
Acute intermittent porphyria, 12
female, 41 years old,
non-acute phase
Porphobilinogen synthase de- 12
ficiency porphyria, male, 36
years old, non-acute phase
Variegate porphyria, female, 229
28 years old, non-acute
phase
Hereditary coproporphyria, 939
female, 29 years old, acute
phase (fig. Ib)
2566
924
43
41
27
1180
37
Controls,
upper reference limit (6)
37 151
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dized with an aqueous solution of 10 mg 12 and 20 mg KI for 10
rain, and treated with Na2S2O3 to eliminate surplus iodine. Porphy-
rins were extracted with 2 ml of 1.5 mol/1 HCl/methanol/iso-propa-
nol (16 + 3 4- 3, by vol.) (8). After vortexing and centrifugation
at 2500 £ for 10 min, 5 ml 1.2 mol/1 H3PO4 were added to the
supernatant. The porphyrins were then adsorbed on 100 mg
LiChroprep RP-18 material (25—40 μπι, Merck, Darmstadt, Ger-
many), washed with water and eluted with methanol/acetone
(1 + 1, by vol.).
Free porphyrin carboxylic acids were separated on reversed-phase
pre-coated TLC plates (RP-18F, 0.25 mm layer thickness, Merck)
using 0.1 mol/1 ammonium acetate (pH 4.1)/20 mmol/1 tetrabutyi-
ammonium phosphate (pH 7.2)/acetone/methanol (35 -1-15 +60
-f 20, by vol.) as the mobile phase. Coproporphyrins (RF value
0.18) were eluted with acetone, the solvent was removed and the
residue dissolved in 200 μΐ 50 mmol/l methanolic tetrabutylam-
monium phosphate (pH 7.2) prior to HPLC analysis.
as compared with the previously used methyl ester
method (16).
HPLC analysis
The four coproporphyrin isomers I—IV were completely
separated by isocratic ion-pair HPLC as described pre-
viously (5). This highly selective isolation procedure
provides clean chromatograms for faecal coproporphy-
rins, which were not affected by interfering substances
(fig. la, b). Some minor extraneous peaks were observed
only in stool samples from patients with chronic hepatic
porphyria, e. g., porphyria cutanea tarda.
HPLC analysis
Simultaneous separation of the four coproporphyrin isomers I—IV
was performed by isocratic ion-pair HPLC on a 5 μιη LiChrosorb
RP-18 column (Merck) using tetrabutylammonium phosphate as
the ion-pairing reagent (5). The isomer proportions were calculated
from peak area ratios.
Scanning of fluorescence spectra
Fluorescence spectra of the individual coproporphyrin isomers
were recorded with a programmable HPLC fluorescence detector
(model F-1080, Merck), using the stop-flow technique. A slit width
of 10 nm was used. Emission spectra were scanned from 450 to
800 nm after excitation at 396 nm (Soret band). Excitation spectra
were recorded from 250 to 600 nm with the emission wavelength
fixed at 624 nm.
Results and Discussion
Sample preparation method
The presence of coproporphyrinogens in human faeces
was first demonstrated by Fischer & Orth (9) in a
case with congenital erythropoietic porphyria, and later
by Watson et al. (10) in non-porphyric patients. Pudek
et al. (11), however, were unable to detect porphyrino-
gens in a series of stool samples. We started our
sample preparation method with an oxidation step in
order to avoid any non-enzymatic isomerization of the
acidrl bile ροφΓΐ>τίηο$6η5 (12, 13). Once porphyrins
are formed, they are absolutely stable to further isom-
erization.
A combined extraction procedure including hydrochlo-
ric acid and methanol/iso-propanol as organic modifier
was applied to remove chlorophyll derivatives present
in faeces (14).
The naturally occurring coproporphyrin free carboxylic
acids were isolated using a recently developed reversed-
phase ion-pair TLC method, published elsewhere (15).
Direct TLC separation of faecal porphyrin free carbox-
ylic acids is faster and has an increased overall recovery
Fluorescence spectra of coproporphyrin
isomers I — I V
Positive identification of the four coproporphyrin iso-
mers I—IV was achieved by on-line recording of their
emission and excitation fluorescence spectra in faeces
from a patient with hereditary coproporphyria. All four
coproporphyrins exhibited the same emission spectra
with a strong band at 624 nm and a broad shoulder of
low intensity at ca. 670 nm (fig. 2a). In addition, iden-
tical excitation spectra with a characteristic structure
were observed (fig. 2b). The latter showed an intense
Soret band at 396 nm and smaller bands at 500, 536 and
570 nm, respectively. These spectra are comparable to
those of the corresponding absorption spectra. In previ-
ous studies, we confirmed the presence of all four copro-
porphyrin isomers in stool samples of healthy subjects
by on-line diode-array recording of their absorption
spectra (16).
The high sensitivity of fluorescence spectroscopy en-
abled us to scan complete spectra of as little as 1 ng
coproporphyrin on the column.
Methodological criteria
The recovery rates were determined by adding various
amounts of the individual coproporphyrin isomers to
four uniform stool samples containing 67.0% isomer I,
30.5% isomer HI, 0.7% isomer II and 1.8% isomer IV.
The mean analytical recovery was 101 ± 1% (χ ± S. D.)
for isomer I, 98 ± 1% for isomer III, 90 ± 8% for iso-
mer II and 94 ± 4% for isomer IV.
The precision of the method was checked by assaying
seven times a normal stool sample with an isomeric
composition similar to that given above. The resulting
coefficients of variation for isomer I, isomer III, isomer
II and isomer IV were 0.8%, 1.7%, 5.7% and 3.9%,
respectively. Obviously, the precision depends on the
relative abundance of the corresponding isomer.
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Composition of faecal coproporphyrin
isomers I-IV in control subjects and in
various porphyrias
The isomeric composition of faecal coproporphyrins
j_IV
 was determined in 20 control subjects and 60 pa-
tients suffering from the common types of hereditary
porphyria (tab. 2). The ratios of coproporphyrin isomers
III to I and the combined percentages of the atypical
isomers II and IV in individual stool samples are pre-
sented in figs. 3 and 4, respectively.
Copropoiphyrin I was the predominant isomer in faeces
of healthy controls (tab. 2, fig. 3), which agrees with
earlier studies (17-19). High percentages of isomer I
and decreased proportions of isomers II, III and IV were
observed in erythropoietic porphyrias like congenital
erythropoietic porphyria and protqporphyria (tab. 2, figs.
3 and 4).
A significantly higher ratio of coproporphyrin isomers
III to I was found in acute hepatic porphyria, e. g. acute
intermittent porphyria and porphobilinogen synthase2)
Coproporphyrins Coproporphyrins
IV
a)
10 20 30
Retention time [min] b)
10 20 30
Retention time [ min ]
Fig. 1 HPLC separation of faecal coproporphyrin isomers I-IV a = congenital erythropoietic porphyria, I (89.8), ΠΙ (9.1), IV (0.8),
(percentage of total coproporphyrins) from two patients with he- II (0.3).
reditary porphyria. b = hereditary coproporphyria, I (4.0), III (88.8), IV (4.9), II (2.3).
396 nm
624 nm
-m
-ΊΧ
- π
HI
450 500
a)
600
λΓ-nm]
700 800 250 300
b)
400
λ Cnm3
500 600
Fig. 2 a) Fluorescence emission spectra of the faecal copropor- b) Fluorescence excitation spectra of the faecal coproporphyrins
phyrins I-IV from a patient with hereditary coproporphyria I-IV from the same patient as in fig. 2a (wavelength range 250-
(wavelength range 450-800 nm, excitation at 396 nm). The 600 nm, emission at 624 nm). The spectra are overlayed for com-
spectra are overlayed for comparison. parison. »
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deficiency porphyria, in contrast to chronic hepatic por-
phyria like po hyria cutanea tarda (p < 0.005, tab. 3).
In addition, the combined percentages of the atypical
isomers II and IV were significantly higher in acute than
in chronic hepatic porphyria (p < 0.03, tab. 3). In our
study, the isomer III to I ratios of patients with acute
intermittent porphyria exceeded slightly those reported
by Minder (20).
Hereditary coproporphyria and variegate porphyria ex-
hibited markedly elevated isomer III to I ratios (fig. 3),
besides increased proportions of the atypical isomers II
and IV (fig. 4). The predominance of faecal copropor-
phyrin III in hereditary coproporphyria and variegate
porphyria has been reported by others (20—23).
Atypical coproporphyrins II and IV were detected in
each stool sample from both control subjects and por-
phyria patients; the relative content varied between 0.5
and 10.0% of total coproporphyrins. Surprisingly, the
percentages of isomers II and IV were closely correlated
with that of isomer III (r = 0.98), whereas a strong in-
verse correlation was observed in the case of isomer I
(r = -0.97).
Pathobiogenesis of faecal coproporphyrin
isomers I —IV
Formation and excretion of faecal coproporphyrin iso-
mers I—IV in porphyria patients are complex processes,
which may be influenced by several factors, e. g. nature
of the specific enzyme defect, excretion mode of the
individual isomers by the liver cell, relative content of
porphyrinogens, and possible contamination by porphy-
rins of bacterial (24) or dietary (25) origin.
Normally, an isomer ratio of 2 : 1 for coproporphyrins
III and I is found in liver cells (17). The excretion rate
of coproporphyrin I in bile is nearly twofold higher than
that of isomer III (26). Approximately 90% of total
coproporphyrin I is excreted in faeces due to the sup-
erior elimination capacity of bile (18), whereas isomer
III is predominantly found in urine.
Porphyrinogens were detected by Logan et al. (27) in
human bile in substantial amounts, varying between 2
and 32% of total porphyrins. Watson et al. (10) showed
that coproporphyrinogens in bile and faeces account for
2 to 50% of total coproporphyrins.
Coproporphyrinogens can be isomerized in a post-he-
patic, non-enzymatic and pH-dependent process to form
both the physiological isomers I and III, and the atypical
isomers II and IV (12, 28). The isomerization is thermo-
dynamically controlled, so that isomers II and IV are
produced in an obligatory ratio of 1 :2 (12), as con-
firmed in our study (tab. 2). The mechanism of this reac-
tion includes opening of the porphyrinogen ring, forma-
tion of a spirocyclic intermediate, and subsequent re-
arrangement of one pyrrolic moiety (29, 30).
Tab. 2 Isomeric composition of faecal coproporphyrins I—IV (percentage of total coproporphyrins) in
various porphyrias.
Porphyria
Congenital erythropoietic porphyria
Protoporphyria
Porphyria cutanea tarda
Acute intermittent porphyria
N Coproporphyrins*
I
6 88.4 ± 2.9
(83-91)
7 77.6 ± 8.4
(66-88)
13 73.5 ± 10.2
(48-85)
15 62.0 ± 12.5
(30-75)
III
10.2 ± 2.4
(8-15)
21.1 ± 8.3
(12-34)
24.4 ± 9.9
(13-51)
35.3 ± 12.5
(22-69)
II
0.4
(0.2
0.3
(0.1
0.7
(0.3
0.9
(0.3
±0.2
-0.7)
±0.1
-0.5)
±0.4
-2.0)
±0.5
-2.1)
IV
1.0 ±0.4
(0.8 - 1.7)
1.0 ±0.5
(0.4- 1.8)
1.4 ±0.7
(0.7 - 2.9)
1.8 ±0.9
(0.8-4.1)
Porphobilinogen synthase deficiency
porphyria
Variegate porphyria
Hereditary coproporphyria
Controls
2
7
10
20
53.4/45.2
19.7 ± 8.6
(11-32)
5.0 ± 1.0
(3-6)
69.6 ± 6.2
(58-84)
44.2/51.5
74.5 ± 7.9
(63-84)
87.1 ± 2,0
(84-91)
27.5 ± 5.9
(14-40)
0.6/1.0
1.8 ±0.5
(1.3-2.7)
2.4 ± 0.5
(1.7-3.1)
0.9 ± 0.3
(0.3 - 1.6)
1.8/2.3
4.0 ± 0.8
(3.2 - 5.4)
5.5 ± 1.1
(3.8 - 6.9)
2.0 ± 0.8
(0.8 - 4.2)
* mean value ± S.D. (range)
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The elevated excretion of coproporphyrin I in faeces and
urine of patients with congenital erythropoietic por-
phyria is due to the almost complete deficiency of uro-
porphyrinogen ΙΠ cosynthase activity. Presence of
coproporphyrinogen I in faeces of such patients (9)
gives rise to the post-hepatic formation of the atypical
isomers II and IV via non-enzymatic isomerization.
The increased proportion of coproporphyrin I in faeces
of patients with protoporphyria corresponds to that in
urine (4) and originates from hepatic involvement due to
protoporphyrin accumulation (31). The content of biliary
porphyrinogens in protoporphyria patients is very low
(27), so that the formation of the atypical isomers II and
IV is sharply reduced.
The faecal and urinary excretion of coproporphyrin ΙΠ
in patients with either acute intermittent porphyria or
the extremely rare porphobilinogen synthase deficiency
porphyria (32) is significantly higher as compared with
that in porphyria cutanea tarda, resulting from a com-
pensatory counterregulatory enhancement of porphy-
rinogen biosynthesis in the former conditions (32). The
percentages of the atypical isomers II and IV are signifi-
cantly higher in faeces of patients with acute hepatic
porphyria as compared with those in chronic hepatic
porphyria, probably due to a higher excretion of biliary
and/or faecal porphyrinogens in acute hepatic porphyria.
In variegate poiphyria, protoporpnyrinogen and proto-
porphyrin are accumulated because of a deficiency of
protoporphyrinogen oxidase2). The deficient penultimate
step in haem biosynthesis impedes the normal metabo-
10-
ε(D
ο
l r
0.5-
(0
cr
0.1
H-
a e f g
Fig. 3 Ratio of the faecal coproporphyrin isomers ΠΙ to I in pa-
tients with various types of hereditary poiphyria and in control
subjects. Mean values are indicated by horizontal bars. Abbrevi-
ations:
a = congenital erythropoietic porphyria,
b = protoporphyria,
c = poiphyria cutanea tarda,
d = acute intermittent porphyria,
e = porphobilinogen synthase deficiency porphyria,
f = variegate porphyria,
g = hereditary coproporphyria,
h = control subjects.
12-
11-
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Fig. 4 Sum of the faecal coproporphyrin isomers II and IV (%)
in patients with various types of hereditary porphyria and in control
subjects. Mean values are indicated by horizontal bars. Abbrevi-
ations as in fig. 3.
Tab. 3 Comparison of the isomeric composition of faecal copro-
poiphyrins I—IV in acute and chronic hepatic porphyria.
Porphyria Ν
Acute hepatic porphyria
Acute intermittent 17
porphyria,
porphobilinogen
synthase deficiency
porphyria
Ratio of
copro-^
porphyrin
Π Ι : I*
0.70 ± 0.49
(0.30-2.31)
Sum of
copro-
porphyrin
Π + IV (%)*
2.8 ± 1.2
(1.1-6.2)
Chronic hepatic porphyria
Porphyria 13
cutanea tarda
0.36 ± 0.23
(0.15- 1.06)
p < 0.005
2.1 ± 1.1
(1.0-4.9)
p < 0.03
* mean value ± S. D. (r nge)
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lism of the intermediate copΓOpoφhyrinogen III, result-
ing in an increased excretion of coproporphyrin III in
faeces (tab. 2, fig. 3) and urine (4). In addition, the rela-
tively high content of porphyrinogens in the bile of such
patients (ca. 26% of total porphyrins) (27) results in en-
hanced formation of the atypical isomers II and IV in
faeces (tab. 2, fig. 4).
The highest proportions of coproporphyrins II, III and
IV were found in faeces of patients suffering from he-
reditary coproporphyria, where deficient coproporphy-
rinogen oxidase activity is responsible for the largely
raised excretion of isomer III in faeces (tab. 2, fig. 3)
and urine (4). The markedly increased formation of the
atypical isomers II and IV arises from non-enzymatic
isomerization of the abundant coproporphyrinogen III.
Excretion of faecal porphyrins other than
coproporphyrin
Polar porphyrins, e. g., uroporphyrin, hepta- and hexa-
carboxyporphyrin, are normally found in faeces only in
trace amounts. Heptacarboxyporphyrin and especially
isocoproporphyrin are characteristic porphyrins in fae-
ces of patients with chronic hepatic porphyria and its
cutaneous manifestation phase, porphyria cutanea tarda
(1). A minimal increase of coproporphyrins in porphyria
cutanea tarda is common in patients with excessive por-
phyrijauria, whereas faecal protoporphyrin is slightly ele-
vated in cases with heavy alcohol consumption (33).
Increased faecal excretion of pentacarboxyporphyrin can
be found in hereditary coproporphyria and variegate
porphyria together with raised coproporphyrin III levels,
resulting in a ratio of about 1 : 10 (34).
The lipophilic protoporphyrin is exclusively eliminated
via bile and faeces, serving as the essential diagnostic
finding in variegate porphyria (1). An additional rise in
tricarboxypoφhyrin and coproporphyrin III may occur
simultaneously (35).
In harderoporphyria, the recessive variant of hereditary
coproporphyria, a typical increase of the metabolite
harderoporphyrin (tricarboxyporphyrin) is observed (1,
36).
Protoporphyria is characterized by greatly raised eryth-
rocyte protoporphyrin concentration, causing a concomi-
tant protpporphyrinaeniia and increased biliary elimina-
tion of ρΓοΐοροφΙι^Ίΐη. Hepatic involvement due to de-
position of crystalline, hepatotoxic ρΓοίοροφΙτχιίη oc-
curs in about 25% of cases (31). Protoporphynn-mduced
liver complications result in progressive cholestatic cir-
rhosis with a βΐ^φ^ diminished hepatobiliary excretion
capacity for ρπ>ίοροφ1ψπη. Consequently, the erythro-
cyte ρΓοίοροφΙ^Γΐη levels increase even further, which
ultimately may require liver transplantation (37).
Diagnostic relevance of faecal
coproporphyrin isomers I — IV
Greatly increased proportions of faecal ^ρΓοροφΙ^Γΐη
I together with decreased proportions of isomers II, III
and IV are typical findings in the biochemical diagnosis
of congenital erythropoietic porphyna.
In protoporphyna and poφhyria cutanea tarda, patterns
of faecal οορπ)ροφ1^Γίη8 I— IV are similar and cannot
be used to distinguish these two conditions. Although
differences in coproporphynn isomer ratios in poiphyria
cutanea tarda and acute intermittent porphyna as well
as in ροφΙιοΜΙπ^βη synthase deficiency poφhyria are
statistically significant (tab. 3), their diagnostic rele-
vance is compromised by the overlap of ranges (figs.
3 and 4).
The isomer ratios of οορΓοροφ!ν/πη8 III to I display
an extraordinary increase in faeces from patients with
variegate ροφίτ^^ and especially in hereditary copro-
poφhyria as compared with the other ροφ1^ΓΪ35 (fig.
3). Due to the strong positive correlation between the
physiological isomer III and the atypical isomers II and
IV, the latter serve as additional diagnostic markers (fig.
4). For example, the percentage of οορΓοροφΙ^πη IV
exceeds that of isomer I in faeces of patients with hered-
itary οορΓοροφΙ^η^ (fig. Ib). Variegate poφhyria and
hereditary ^ρΓοροφ1^Γί3 can be clearly distinguished
by comparing the respective excretion of faecal copro-
porphynns and ρΓΟίοροφΙτ/ηη (tab. 1) (1).
Analysis of faecal coproporphyrin isomers
I — IV in a family with hereditary
coproporphyria
The ratio of faecal ^ρΓοροφΙ^ιίη isomers III to I was
used successfully for screening adult patients at risk of
hereditary coproperphyna in a large family study by
Blake et al. (22), and by Sieg & Doss (38).
In our study, we analysed the total faecal
rins and the relative proportions of the isomers I— IV in
6 members of a family with hereditary οορπ>ροφ!ΐ)α^
(tab. 4). The index patient of this family (daughter 1)
presented with severe abdominal attacks. She excreted
large amounts of faecal οορΓοροφΙτ^τίηβ with greatly
raised proportions of the physiological isomer III be-
sides the atypical isomers II and IV (tab. 4). Her father,
her sister and her brother 2 excreted elevated amounts of
faecal οορΓοροφΙ^Γΐη5, too, and nearly identical isomer
ratios. Here, the combined determination of total faecal
and the isomeric composition of copro-
Eur J Clin Chem Clin Biochem 1995; 33 (No 12)
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Tab. 4 Composition of faecal coproporphyrin isomers I-IV in a family with hereditary
coproporphyria.
Member of the family
Father
Mother
Daughter 1*
Daughter 2
Son 1
Son 2
Controls
Total
coproporphyrins
(nmol/g dry weight)
530
12
6735
551
25
4320
5-37
Ratio of
coproporphyrin III : I
14.0
0.3
16.9
15.5
0.5
17.5
0.4 ± 0.2
Sum of
coproporphyrin II + IV
(%)
5.6 , ,
0.9
7.1
7.4
2.7
9.3
2.7 ± 1.3
Gene
carrier
+
+
+
+
-
* Index patient
porphyrins I —IV designated them as carriers of the defi- like acute intermittent porphyria and porphobilinogeri
cient coproporphyrinogen oxidase2) gene, although they synthase deficiency porphyria as compared with por-
were so far clinically asymptomatic. On the other hand, phyria cutanea tarda, the diagnostic value of these fmd-
the mother and the brother 1 of the index patient showed ings is compromised by an overlap of ranges.
normal excretion of total faecal coproporphyrins and a
normal composition of the four coproporphyrin isomers, ™e m°f ly increased Pr°P°rtions of faec^ copropor-
which makes the presence of a deficient coproporphy- phyrms m· Π and ^  toSether with markedly decreased
rinogen oxidase gene unlikely. proportions of isomer I, are found in variegate porphyria
and especially in hereditary coproporphyria, providing a
Thus, analysis of total faecal coproporphyrins, combined good diagnostic marker for these conditions.
with the proportions of their isomers I-IV, provided a
simple identification of affected members in this family In family studies> automatic gene carriers for heredi-
with hereditary copropoiphyria, and it confirmed previ- tary ^Proporphyria with normal faecal excretion of
ous findings with isomers I and III (22, 38). Analysis of ^Ρ^ΡΟΦ^Π^ can be detected by the inversion of
urinary coproporphyrin isomers in the same subjects their 00ΡΓΟΡ°Φ1ιΥΓίη «I to I ratio. Individuals with latent
(data not shown) showed inadequate diagnostic sensitiv- phases of hereditary coproporphyria, characterized by a
ity and did not allow identification of carriers of the slight to moderate ^crease of faecal coproporphyrins
genetic defect. (and urinary coproporphyrins too), are also diagnosed
by the dominance of isomer III.
. Thus, determination of the proportions of faecal copro-
onc usion porphyrin isomers I-IV offers valuable information for
An improved sample preparation method enabled the re- the dkgposis and differential diagnosis of porphyrias.
liable determination of the four coproporphyrin isomers The dynamic ranSe of faecal eoproporphyrin isomer ra-
I— IV in faeces of porphyria patients. ^os *s more pronounced than that of urinary copropor-
n «, . , . phyrins; in addition, the atypical isomers II and IV con-Greatly increased proporttons of coproporphyrin I and
 Αΐ6 to the diagnostic i ^ of feecal
decreased proportions of isomers III, II and IV are diag- phyrins.
nostically relevant in erythropoietic porphyria, namely
congenital erythropoietic porphyria and protoporphyria.
Similar results can be obtained from the analysis of Acknowledgements '
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